Site-specific mutations in PIK3CA have been shown to have varying responses to treatment, with evidence suggesting a greater response to PI3K/AKT/mTOR pathway inhibitors for tumors with mutations in the H1047R kinase domain (which are not commonly found in cervical cancers) compared with mutations at other sites [133]. This evidence concerns the gene MTOR and cervical carcinoma.